{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:19Z","timestamp":1781795779273,"version":"3.54.5"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamadermatol.2019.2941","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T21:20:27Z","timestamp":1571260827000},"page":"1380","source":"Crossref","is-referenced-by-count":9,"title":["Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis"],"prefix":"10.1001","volume":"155","author":[{"given":"Miriam","family":"Zidane","sequence":"first","affiliation":[{"name":"Division of Evidence-Based Medicine, Klinik f\u00fcr Dermatologie, Venerologie and Allergologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Dressler","sequence":"additional","affiliation":[{"name":"Division of Evidence-Based Medicine, Klinik f\u00fcr Dermatologie, Venerologie and Allergologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gaskins","sequence":"additional","affiliation":[{"name":"Division of Evidence-Based Medicine, Klinik f\u00fcr Dermatologie, Venerologie and Allergologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[{"name":"Division of Evidence-Based Medicine, Klinik f\u00fcr Dermatologie, Venerologie and Allergologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi190052r1","first-page":"S1","article-title":"S3-guidelines for the treatment of psoriasis vulgaris, update 2011 [in German].","volume":"9","author":"Nast","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"doi190052r3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence.","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi190052r4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.sder.2010.02.002","article-title":"Safety and efficacy of the tumor necrosis factor antagonists.","volume":"29","author":"Bachmann","year":"2010","journal-title":"Semin Cutan Med Surg"},{"issue":"8","key":"doi190052r5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/jid.2013.78","article-title":"Which antipsoriatic drug has the fastest onset of action? systematic review on the rapidity of the onset of action.","volume":"133","author":"Nast","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi190052r6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjd.12706","article-title":"Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris.","volume":"170","author":"Jacobs","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190052r7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"issue":"11","key":"doi190052r8","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis.","volume":"135","author":"Nast","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi190052r9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjd.2008.159.issue-3","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi190052r10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1365-2133.1997.tb01556.x","article-title":"A systematic review of five systemic treatments for severe psoriasis.","volume":"137","author":"Spuls","year":"1997","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi190052r11","first-page":"1442","article-title":"Conventional systemic agents for psoriasis: a systematic review.","volume":"33","author":"Strober","year":"2006","journal-title":"J Rheumatol"},{"issue":"9","key":"doi190052r12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/archderm.143.9.1175","article-title":"Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis.","volume":"143","author":"Seston","year":"2007","journal-title":"Arch Dermatol"},{"issue":"2","key":"doi190052r13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/09546630903551258","article-title":"Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.","volume":"22","author":"Anis","year":"2011","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"doi190052r14","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1185\/030079907X210688","article-title":"Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.","volume":"23","author":"Bottomley","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"doi190052r15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jval.2011.01.006","article-title":"Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.","volume":"14","author":"Pan","year":"2011","journal-title":"Value Health"},{"issue":"9","key":"doi190052r16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40273-013-0078-x","article-title":"Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.","volume":"31","author":"Villacorta","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"9993","key":"doi190052r17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"doi190052r18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-013-0030-z","article-title":"Cost effectiveness of biologic therapies for plaque psoriasis.","volume":"14","author":"Ahn","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"doi190052r19","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1111\/dth.2010.23.issue-s1","article-title":"Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system [published correction appears in Dermatol Ther. 2010;23(4):434].","volume":"23","author":"de Portu","year":"2010","journal-title":"Dermatol Ther"},{"issue":"2","key":"doi190052r20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/09546630600552273","article-title":"New treatments for psoriasis: which biologic is best?","volume":"17","author":"Nelson","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"doi190052r21","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"doi190052r23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1477-7525-1-53","article-title":"Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.","volume":"1","author":"Shikiar","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"doi190052r24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/000155500300012873","article-title":"Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity.","volume":"80","author":"Lundberg","year":"2000","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi190052r25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1046\/j.1365-2133.1999.03112.x","article-title":"Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI.","volume":"141","author":"Badia","year":"1999","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi190052r26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaad.2007.09.018","article-title":"Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.","volume":"58","author":"Nelson","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190052r27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00403-012-1309-2","article-title":"Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.","volume":"305","author":"Blome","year":"2013","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"doi190052r28","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1517\/14656566.4.9.1525","article-title":"Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.","volume":"4","author":"Feldman","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"doi190052r29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12325-012-0035-7","article-title":"Cost per responder associated with biologic therapies for Crohn\u2019s disease, psoriasis, and rheumatoid arthritis.","volume":"29","author":"Liu","year":"2012","journal-title":"Adv Ther"},{"issue":"2","key":"doi190052r30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjd.2009.160.issue-2","article-title":"Economic evaluation of etanercept in the management of chronic plaque psoriasis.","volume":"160","author":"Lloyd","year":"2009","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190052r31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/09546634.2010.542800","article-title":"Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.","volume":"22","author":"Martin","year":"2011","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"doi190052r32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000086444","article-title":"Cost-effectiveness of once-daily treatment with calcipotriol\/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris.","volume":"211","author":"Peeters","year":"2005","journal-title":"Dermatology"},{"key":"doi190052r33","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.2310\/7750.2009.00021","article-title":"Biologics in the treatment of psoriasis: clinical and economic overview.","volume":"13","author":"Poulin","year":"2009","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"doi190052r34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjd.2014.170.issue-2","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190052r35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/jde.2010.37.issue-4","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study.","volume":"37","author":"Asahina","year":"2010","journal-title":"J Dermatol"},{"issue":"3","key":"doi190052r36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190052r37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis.","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"doi190052r38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190052r39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9271","key":"doi190052r40","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"doi190052r41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi190052r42","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi190052r43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, placebo-controlled multicenter trial.","volume":"59","author":"Torii","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"11","key":"doi190052r44","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.","volume":"125","author":"Yang","year":"2012","journal-title":"Chin Med J (Engl)"},{"issue":"10068","key":"doi190052r45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"doi190052r46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi190052r47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190052r48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION).","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi190052r49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/0001555577137141","article-title":"Low-dose (1.25 mg\/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.","volume":"77","author":"Meffert","year":"1997","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi190052r50","first-page":"A69","article-title":"Dimethyl fumarate (BG00012) as an oral therapy for moderate to severe psoriasis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"125","author":"Mrowietz","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi190052r51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm- and placebo-controlled trial (BRIDGE).","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br J Dermatol"},{"issue":"9494","key":"doi190052r52","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"doi190052r53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"doi190052r54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.2015.172.issue-2","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190052r55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"doi190052r56","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE).","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi190052r57","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial.","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"3","key":"doi190052r58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190052r59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00296-019-04244-5","article-title":"Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.","volume":"39","author":"Pham","year":"2019","journal-title":"Rheumatol Int"},{"issue":"1","key":"doi190052r60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1046\/j.1365-2133.1998.02319.x","article-title":"A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis: OLP302 Study Group.","volume":"139","author":"Koo","year":"1998","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190052r61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/09546634.2011.565017","article-title":"Combined treatment with low-dose cyclosporine and calcipotriol\/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.","volume":"23","author":"Vena","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"doi190052r62","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.2006.154.issue-6","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.","volume":"154","author":"Reich","year":"2006","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi190052r63","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/archderm.138.9.1221","article-title":"The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review.","volume":"138","author":"De Korte","year":"2002","journal-title":"Arch Dermatol"},{"key":"doi190052r64","first-page":"50","article-title":"Clinical meaning of change in Dermatology Life Quality Index scores.","volume":"147","author":"Khilji","year":"2002","journal-title":"Br J Dermatol"},{"issue":"32","key":"doi190052r65","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1016\/j.vaccine.2015.06.084","article-title":"Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review.","volume":"33","author":"Jit","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"doi190052r66","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"doi190052r67","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13075-015-0814-z","article-title":"Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.","volume":"17","author":"Hawwa","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"doi190052r68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"doi190052r69","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00403-013-1372-3","article-title":"Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis\u2014a multinational cross-sectional study.","volume":"305","author":"Nast","year":"2013","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"doi190052r70","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/jme.2003.007047","article-title":"Ethical issues of cost effectiveness analysis and guideline setting in mental health care.","volume":"30","author":"Berghmans","year":"2004","journal-title":"J Med Ethics"},{"issue":"5","key":"doi190052r71","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/bjd.16716","article-title":"Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments.","volume":"179","author":"Boswell","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi190052r72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.2018.32.issue-1","article-title":"Cost-of-illness of psoriasis\u2014results of a German cross-sectional study.","volume":"32","author":"Jungen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi190052r73","first-page":"617","article-title":"Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study.","volume":"24","author":"Feldman","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"doi190052r74","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/jdv.2018.32.issue-10","article-title":"Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.","volume":"32","author":"Talamonti","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi190052r75","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2016.02.1221","article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.","volume":"75","author":"Yamauchi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"doi190052r22","year":"2013"},{"key":"doi190052r2","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management. http:\/\/nice.org.uk\/guidance\/cg153. Updated September 2017. Accessed March 8, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2753126\/jamadermatology_zidane_2019_oi_190052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:17:42Z","timestamp":1695323862000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2753126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.2941","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}